Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 5
2009 3
2010 11
2011 8
2012 5
2013 1
2014 2
2015 4
2016 4
2017 1
2018 7
2019 11
2020 11
2021 15
2022 14
2023 13
2024 11
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

113 results

Results by year

Filters applied: . Clear all
Page 1
Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer.
Bancaro N, Calì B, Troiani M, Elia AR, Arzola RA, Attanasio G, Lai P, Crespo M, Gurel B, Pereira R, Guo C, Mosole S, Brina D, D'Ambrosio M, Pasquini E, Spataro C, Zagato E, Rinaldi A, Pedotti M, Di Lascio S, Meani F, Montopoli M, Ferrari M, Gallina A, Varani L, Pereira Mestre R, Bolis M, Gillessen Sommer S, de Bono J, Calcinotto A, Alimonti A. Bancaro N, et al. Among authors: gurel b. Cancer Cell. 2023 Mar 13;41(3):602-619.e11. doi: 10.1016/j.ccell.2023.02.004. Epub 2023 Mar 2. Cancer Cell. 2023. PMID: 36868226 Free article.
B7-H3 as a Therapeutic Target in Advanced Prostate Cancer.
Guo C, Figueiredo I, Gurel B, Neeb A, Seed G, Crespo M, Carreira S, Rekowski J, Buroni L, Welti J, Bogdan D, Gallagher L, Sharp A, Fenor de la Maza MD, Rescigno P, Westaby D, Chandran K, Riisnaes R, Ferreira A, Miranda S, Calì B, Alimonti A, Bressan S, Nguyen AHT, Shen MM, Hawley JE, Obradovic A, Drake CG, Bertan C, Baker C, Tunariu N, Yuan W, de Bono JS. Guo C, et al. Among authors: gurel b. Eur Urol. 2023 Mar;83(3):224-238. doi: 10.1016/j.eururo.2022.09.004. Epub 2022 Sep 13. Eur Urol. 2023. PMID: 36114082 Free PMC article.
Targeting the p300/CBP Axis in Lethal Prostate Cancer.
Welti J, Sharp A, Brooks N, Yuan W, McNair C, Chand SN, Pal A, Figueiredo I, Riisnaes R, Gurel B, Rekowski J, Bogdan D, West W, Young B, Raja M, Prosser A, Lane J, Thomson S, Worthington J, Onions S, Shannon J, Paoletta S, Brown R, Smyth D, Harbottle GW, Gil VS, Miranda S, Crespo M, Ferreira A, Pereira R, Tunariu N, Carreira S, Neeb AJ, Ning J, Swain A, Taddei D; SU2C/PCF International Prostate Cancer Dream Team; Schiewer MJ, Knudsen KE, Pegg N, de Bono JS. Welti J, et al. Among authors: gurel b. Cancer Discov. 2021 May;11(5):1118-1137. doi: 10.1158/2159-8290.CD-20-0751. Epub 2021 Jan 11. Cancer Discov. 2021. PMID: 33431496 Free PMC article.
Genomics of lethal prostate cancer at diagnosis and castration resistance.
Mateo J, Seed G, Bertan C, Rescigno P, Dolling D, Figueiredo I, Miranda S, Nava Rodrigues D, Gurel B, Clarke M, Atkin M, Chandler R, Messina C, Sumanasuriya S, Bianchini D, Barrero M, Petermolo A, Zafeiriou Z, Fontes M, Perez-Lopez R, Tunariu N, Fulton B, Jones R, McGovern U, Ralph C, Varughese M, Parikh O, Jain S, Elliott T, Sandhu S, Porta N, Hall E, Yuan W, Carreira S, de Bono JS. Mateo J, et al. Among authors: gurel b. J Clin Invest. 2020 Apr 1;130(4):1743-1751. doi: 10.1172/JCI132031. J Clin Invest. 2020. PMID: 31874108 Free PMC article. Clinical Trial.
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.
Guo C, Sharp A, Gurel B, Crespo M, Figueiredo I, Jain S, Vogl U, Rekowski J, Rouhifard M, Gallagher L, Yuan W, Carreira S, Chandran K, Paschalis A, Colombo I, Stathis A, Bertan C, Seed G, Goodall J, Raynaud F, Ruddle R, Swales KE, Malia J, Bogdan D, Tiu C, Caldwell R, Aversa C, Ferreira A, Neeb A, Tunariu N, Westaby D, Carmichael J, Fenor de la Maza MD, Yap C, Matthews R, Badham H, Prout T, Turner A, Parmar M, Tovey H, Riisnaes R, Flohr P, Gil J, Waugh D, Decordova S, Schlag A, Calì B, Alimonti A, de Bono JS. Guo C, et al. Among authors: gurel b. Nature. 2023 Nov;623(7989):1053-1061. doi: 10.1038/s41586-023-06696-z. Epub 2023 Oct 16. Nature. 2023. PMID: 37844613 Free PMC article.
BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity.
Westaby D, Jiménez-Vacas JM, Figueiredo I, Rekowski J, Pettinger C, Gurel B, Lundberg A, Bogdan D, Buroni L, Neeb A, Padilha A, Taylor J, Zeng W, Das S, Hobern E, Riisnaes R, Crespo M, Miranda S, Ferreira A, Hanratty BP, Nava Rodrigues D, Bertan C, Seed G, Fenor de La Maza MLD, Guo C, Carmichael J, Grochot R, Chandran K, Stavridi A, Varkaris A, Stylianou N, Hollier BG, Tunariu N, Balk SP, Carreira S, Yuan W, Nelson PS, Corey E, Haffner M, de Bono J, Sharp A. Westaby D, et al. Among authors: gurel b. J Clin Invest. 2024 Sep 17;134(18):e179998. doi: 10.1172/JCI179998. J Clin Invest. 2024. PMID: 39286979 Free PMC article.
Elucidating acquired PARP inhibitor resistance in advanced prostate cancer.
Seed G, Beije N, Yuan W, Bertan C, Goodall J, Lundberg A, Tyler M, Figueiredo I, Pereira R, Baker C, Bogdan D, Gallagher L, Cieslik JP, Greening S, Lambros M, Neves R, Magraner-Pardo L, Fowler G, Ebbs B, Miranda S, Flohr P, Bianchini D, Rescigno P, Porta N, Hall E, Gurel B, Tunariu N, Sharp A, Pettit S, Stoecklein NH, Sandhu S, Quigley D, Lord CJ, Mateo J, Carreira S, de Bono J. Seed G, et al. Among authors: gurel b. Cancer Cell. 2024 Dec 9;42(12):2113-2123.e4. doi: 10.1016/j.ccell.2024.10.015. Epub 2024 Nov 21. Cancer Cell. 2024. PMID: 39577422 Free PMC article.
Prostate carcinogenesis: inflammatory storms.
de Bono JS, Guo C, Gurel B, De Marzo AM, Sfanos KS, Mani RS, Gil J, Drake CG, Alimonti A. de Bono JS, et al. Among authors: gurel b. Nat Rev Cancer. 2020 Aug;20(8):455-469. doi: 10.1038/s41568-020-0267-9. Epub 2020 Jun 16. Nat Rev Cancer. 2020. PMID: 32546840 Review.
HER3 Is an Actionable Target in Advanced Prostate Cancer.
Gil V, Miranda S, Riisnaes R, Gurel B, D'Ambrosio M, Vasciaveo A, Crespo M, Ferreira A, Brina D, Troiani M, Sharp A, Sheehan B, Christova R, Seed G, Figueiredo I, Lambros M, Dolling D, Rekowski J, Alajati A, Clarke M, Pereira R, Flohr P, Fowler G, Boysen G, Sumanasuriya S, Bianchini D, Rescigno P, Aversa C, Tunariu N, Guo C, Paschalis A, Bertan C, Buroni L, Ning J, Carreira S, Workman P, Swain A, Califano A, Shen MM, Alimonti A, Neeb A, Welti J, Yuan W, de Bono J; PCF/SU2C International Prostate Cancer Dream Team. Gil V, et al. Among authors: gurel b. Cancer Res. 2021 Dec 15;81(24):6207-6218. doi: 10.1158/0008-5472.CAN-21-3360. Epub 2021 Nov 9. Cancer Res. 2021. PMID: 34753775 Free PMC article.
Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy.
Al-Janabi H, Moyes K, Allen R, Fisher M, Crespo M, Gurel B, Rescigno P, de Bono J, Nunns H, Bailey C, Junker-Jensen A, Muthana M, Phillips WA, Pearson HB, Taplin ME, Brown JE, Lewis CE. Al-Janabi H, et al. Among authors: gurel b. J Immunother Cancer. 2024 Jul 25;12(7):e009368. doi: 10.1136/jitc-2024-009368. J Immunother Cancer. 2024. PMID: 39060021 Free PMC article.
113 results